Vivos Q2 revenue falls to $3.4M (-19% YoY); net loss narrows 21% but now expects added financing

Vivos Therapeutics, Inc.

2023-Q2 EPS reported -$0.26 revenue$7,253,000

Revenue $3.4M, down 19% YoY from $4.2M; gross profit $2.1M (62% margin).
Net loss reduced by $1.5M (21% YoY) reflecting cost cuts.
Operating expenses cut 31% YoY ($2.9M reduction).
Cash $3.9M; now expects to need additional financing as sales growth stalled.
Patients treated ~40,000 (up from ~28,000); DSO pilots and first DME distribution deal signed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vivos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $3.4 million.

Period: the second quarter ended June 30, 2023
Revenue: $3.4 million
Result: reported results

Exact text from the filing

reported financial results and operating highlights for the second quarter and six months ended June 30, 2023. Second Quarter 2023 Financial and Operating Summary ● Revenue was $3.4 million for the second quarter of 2023 and $7.3 million for the six months ended June 30, 2023, compared to $4.2 million and $7.8 million for the three and six months ended June 30,

View on SEC.gov

Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.